title: [Evaluation of implantable sites in medical oncology in Tunisia. Prospective study of 205 cases].
abstract: OBJECTIVE
  To evaluate the insertion and use of implantable central venous accesses in medical oncology at the Institute Salah Azaïz.
  
  
  METHODS
  From January 1992 to June 2000, 205 patients including 179 adults (118F/61M) and 26 children aged 7 months to 72 years (mean 37 years) required the insertion of an implantable port (IP). Tumoral pathology was dominated by metastatic breast carcinoma (93/179), digestive cancer (42/179) and paediatric cancer (26 cases).
  
  
  RESULTS
  Excluding 3 initial failures, we inserted 205 IP for 202 patients. The supraclavicular anatomic way (Yoffa) was used in 156/205 cases and the subclavicular (Aubaniac) for the resting 32 cases with a jugular conversion in 17 cases. Initial complications were represented by 6 arterial puncture (2.9%), 3 pneumothorax (1.5%) and 1 catheter migration in the right pulmonary artery. Median life duration of the material was 210 days (3 to 1460 days) for adults and 185 days (3 to 1460 ays) for children. Mean life duration for the 205 IP was 240 days +/- 239 (3 to 1460 days) with a total of 49,200 IP-days. We explanted 17 IP for infection (8 cases), cutaneous ulceration (8 cases) and actinomycin extravasation (1 case). We observed 6 cases (2.9%) of subclavian and jugular thrombosis treated by anticoagulants and conservation management of the port. Presently, 58 patients are alive with IP in place.
  
  
  CONCLUSIONS
  Implantable ports represent a useful option in medical oncology for patients treated with prolonged chemotherapy and adjuvant treatments such as antibiotics, transfusion. This method allows a good comfort for the patients and also the treating team but requires a prealable training for the nursing team.
authors.affiliation: Service de carcinologie médicale, Institut Salah Azaïz, boulevard du 9 avril, Bab Saadoun, Tunis, Tunisie. hamouda.boussen@rns.tn
authors.forename: H
authors.initials: H
authors.lastname: Boussen
authors.forename: M
authors.initials: M
authors.lastname: Mtaallah
authors.forename: T
authors.initials: T
authors.lastname: Dhiab
authors.forename: S
authors.initials: S
authors.lastname: Khalfallah
authors.forename: G
authors.initials: G
authors.lastname: Jerbi
authors.forename: M
authors.initials: M
authors.lastname: Hechiche
authors.forename: A
authors.initials: A
authors.lastname: Mezlini
authors.forename: K
authors.initials: K
authors.lastname: Rahal
authors.forename: F
authors.initials: F
authors.lastname: Ben Ayed
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002408:Catheters, Indwelling; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents